Psychopharmacology at the era of EMEA (European Medicines Agency)
نویسندگان
چکیده
In the last decade the European Medicines Agency has been attempting to harmonize the work of the existing national medicines regulatory authorities and the data regarding efficacy criteria and safety for the use of human medicines in specific pathologies (eg. Schizophrenia, Bipolar Disorder, Depression), thus creating guidance notes for clinical investigation. Medical prescription decisions are generally made upon data acquired through scientific information (treatise, studies, consensus, meetings, congresses), specialists experience and pharmaceutical industry information. While prescription rules are established for approved indications by large scale studies, off-label prescribing lacks the support of robust clinical trials and is at its best based on expert consensus. It brings with it increased responsibility for the prescriber if the patient suffered an adverse reaction, as liability would rest with the prescriber and/ or their employers. Nuclear information for a rational plan, risk assessment, scientific evidence for add-on therapy and off-label prescription, will be discussed in this presentation.
منابع مشابه
Regulatory policies on medicines for psychiatric disorders: is Europe on target?
The European Medicines Agency (EMEA) is the regulatory body that provides the institutions of the European Community with the best possible scientific advice on the quality, safety and efficacy of medicinal products. Drugs approved by the EMEA are automatically marketable in all the European member states. Since the beginning of the EMEA's activities a number of drugs acting on the central nerv...
متن کاملPHARMACOEPIDEMIOLOGY AND PRESCRIPTION Medicines for children licensed by the European Medicines Agency (EMEA): the balance after 10 years
Objective The 1995–2005 balance of EMEA activities in the field of paediatric medicines was evaluated, taking into account the number both of drugs authorised for children and paediatric studies supporting the Marketing Authorisation (MA). Methods Data on drugs authorised by EMEA were extracted from EPARs (European Public Assessment Reports). Active substance, year of approval, anatomical, ther...
متن کاملThe European Agency for the Evaluation of Medicinal Products Veterinary Medicines Evaluation Unit EMEA/CVMP/315/98 - FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS NOTE FOR GUIDANCE: DEVELOPMENT PHARMACEUTICS FOR VETERINARY MEDICINAL PRODUCTS RELEASED FOR CONSULTATION BY CVMP
متن کامل
ENVIRONMENTAL RISK ASSESSMENT (ERA) OF PHARMACEUTICALS AND PERSONAL CARE PRODUCTS (PPCPs) USING ECOTOXICITY TESTS
A wide range of Pharmaceuticals and Personal Care Products (PPCPs) are present in the environment, and many of their adverse effects are unknown. The environmental risk assessment (ERA) of twenty six PPCPs of high consumption and occurrence in Spain was done in this work. Based on ecotoxicity values obtained by bioluminescence and respirometry assays, the compounds were classified as establishe...
متن کاملThe European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use
In December 2000, following 10 cases of life-threatening cardiac disorders including ventricular rhythm disorders such as Torsade de pointes reported in patients treated with Orlaam (levacethylmethadol), the European Medicines Evaluation Agency's (EMEA) scientific committee, the Committee for Proprietary Medicinal Products (CPMP), had decided, as an interim and precautionary measure while perfo...
متن کامل